

Freedom of Information Request: Our Reference CTMUHB_193_20

You asked:

1. Within your Health Board, how many patients, in the most recent 12-month period for which data are available, have received anti-VEGF treatment for the first time (i.e., excluding patients who previously had any anti-VEGF therapy)?
2. Of these first-time patients, please provide a breakdown by the treatments listed below:
 - Aflibercept
 - Brolucizumab
 - Dexamethasone
 - Ranibizumab
 - All other anti-VEGF treatments
3. Of these first-time patients, how many were treated for Wet Age-Related Macular Degeneration (wAMD) by each treatment?
 - Aflibercept
 - Brolucizumab
 - Dexamethasone
 - Ranibizumab
 - All Other anti-VEGF treatments

Our response:

In response to your request the table one below has been populated with the number of recorded 1st anti-VEGF treatment administered during the period of 1st April 2019 and 31st March 2020 by medicine and for the conditions of DMO, RVO, CNV, DMO Secondary to RVO, Uveitis, CDMO and includes AMD. Unfortunately, due to the way the data is collected we are unable to identify those eyes that have previously been treated with and anti-VEGF treatment.

Medicine	Total Number of 1st Injections
TOTAL	3143
Aflibercept	1991
Ranibizumab	1150
Dexamethasone	5
Brolucizumab	0

Please see data for AMD only provided below:

Medicine	Total Number of 1st Injections for AMD
TOTAL	2821
Aflibercept	1721
Ranibizumab	1100
Dexamethasone	0
Brolucizumab	0